Home/Pipeline/Influenza mAb Programs

Influenza mAb Programs

Influenza

Discovery/PreclinicalActive (Research)

Key Facts

Indication

Influenza

Phase

Discovery/Preclinical

Status

Active (Research)

Company

Invivyd

About Invivyd

Invivyd's mission is to deliver protection from serious viral infectious diseases by developing rapidly-adaptable monoclonal antibody therapies. The company has achieved key milestones, including positive Phase 3 results for its COVID-19 candidate and an Emergency Use Authorization from the U.S. FDA. Its strategy leverages a proprietary, integrated technology platform to monitor viral evolution and engineer potent, variant-resistant antibodies, positioning it as a critical player in pandemic preparedness and the management of endemic viral diseases.

View full company profile

Therapeutic Areas

Infectious Disease Respiratory Diseases

Other Influenza Drugs

Drug	Company	Phase	Status
PanCytoVir™ (oral probenecid)	TrippBio	IND Submitted	Active
Mimotopes-004	Mimotopes	Preclinical	Active
Next-Gen / Universal Flu Vaccines	CSL Seqirus	Research / Early Clinical	Active
Oseltamivir 75 mg	MSN Laboratories	Commercial	Active
AI Programme - Influenza	Poolbeg Pharma	Discovery	Active - Target/Candidate ID
Influenza Antibodies	new/era/mabs	Research/Pre-clinical	Active
Influenza Countermeasure Program	DynPort Vaccines	Not Specified	Active
Influenza Vaccine	Medigen	Preclinical	Active
Nasal Influenza Vaccine	Abera Bioscience	Pre-clinical	Active
Zapnometinib (ATR-002)	Atriva Therapeutics	Phase 2	Active
EV25	Eradivir	Pre-clinical	Active
Not Specified	New Amsterdam Sciences	Pre-clinical	Active